Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Low dose 2-CdA schedule activity in splenic marginal zone lymphomas.

R Riccioni1, F Caracciolo, S Galimberti

  • 1Haematology Division, Department of Oncology, Transplant and Advanced Technologies, University of Pisa, Italy.

Hematological Oncology
|January 22, 2004
PubMed
Summary

Cladribine shows promise for treating Splenic Marginal Zone Lymphoma (SMZL), a rare blood cancer. This treatment is safe, well-tolerated, and achieved significant responses, offering a potential alternative to splenectomy for patients with this indolent lymphoma.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Second-line therapies after CDK4/6 inhibitor failure in HR-positive/HER2-negative metastatic breast cancer patients: real-world data from the HERMIONE-13 study.

ESMO real world data and digital oncology·2026
Same author

Choice of Frontline Tyrosine-Kinase Inhibitor and Early Events in Very Elderly Patients With Chronic Myeloid Leukemia in Chronic Phase: A "Campus CML" Study.

European journal of haematology·2024
Same author

Examining linkages among multiple sustainable development outcomes: does the productive safety net program increase on-farm agrobiodiversity?

Environment, development and sustainability·2023
Same author

Chronic lip edema and pain secondary to lip augmentation procedure: histological, scanning electron microscopy and X-ray microanalysis evaluation.

European review for medical and pharmacological sciences·2023
Same author

Treatment discontinuation following low-dose TKIs in 248 chronic myeloid leukemia patients: Updated results from a campus CML real-life study.

Frontiers in pharmacology·2023
Same author

Carboxytherapy with oxygen propulsion treatment of cellulite is more effective in women not affected by periodontal disease.

Journal of biological regulators and homeostatic agents·2021

Area of Science:

  • Hematology
  • Oncology
  • Clinical Therapeutics

Background:

  • Splenic Marginal Zone Lymphoma (SMZL) is a rare indolent lymphoma.
  • Standard treatment is often splenectomy, but options for aggressive cases or relapsed disease are limited.
  • Identifying effective and well-tolerated therapies is crucial for improving patient outcomes.

Purpose of the Study:

  • To evaluate the safety and efficacy of cladribine in patients with Splenic Marginal Zone Lymphoma.
  • To assess response rates, progression-free survival, and overall survival in SMZL patients treated with cladribine.
  • To explore cladribine as a potential alternative treatment for SMZL.

Main Methods:

  • A cohort of 10 patients with Splenic Marginal Zone Lymphoma received cladribine at a dose of 5 mg/m(2)/week for six courses.

Related Experiment Videos

  • Response rates (complete and partial), progression-free survival (PFS), and overall survival (OS) were assessed.
  • Treatment tolerability and molecular remission were also evaluated.

    • Main Results:

    • Overall response rate was 80% (60% partial response, 20% complete response).
    • Median progression-free survival was 17 months, with 37% of patients achieving 24-month PFS.
    • 60% of patients had an overall survival rate of 48 months, and the treatment was well-tolerated.
    • Some patients achieved molecular remission in addition to hematological remission.

    Conclusions:

    • Cladribine treatment is safe and well-tolerated in Splenic Marginal Zone Lymphoma.
    • This regimen induces a substantial number of hematological and molecular responses.
    • Cladribine offers a potentially useful and effective alternative to splenectomy for SMZL patients.